Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report)’s share price was down 6.5% on Wednesday . The stock traded as low as $1.42 and last traded at $1.51. Approximately 63,476 shares traded hands during mid-day trading, an increase of 283% from the average daily volume of 16,559 shares. The stock had previously closed at $1.61.
Alaunos Therapeutics Trading Down 6.5 %
The stock’s fifty day moving average price is $1.61 and its 200-day moving average price is $2.05.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Featured Articles
- Five stocks we like better than Alaunos Therapeutics
- What Are Earnings Reports?
- Energy Transfer: Powering Data With Dividends and Diversification
- Investing in the High PE Growth Stocks
- Qualcomm Stock Is Coiling for a Breakout
- Upcoming IPO Stock Lockup Period, Explained
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
